ODYS.NASDAQOdysightai INC

S-1/A: Odysight.ai Files Amendment No. 6 to Form S-1 Registration Statement for Resale of Common Stock

Sentiment:

S-1/A Amendment


Odysight.ai is registering the resale of up to 11,046,927 shares of common stock by selling stockholders, including shares obtainable upon warrant exercise.

Worse than expectedThe selling stockholders may exercise their warrants at below-market prices, which would be dilutive of current stockholders.The resale of shares could cause a significant decline in the trading price of the common stock.

Summary

  • Odysight.ai Inc. has filed Amendment No. 6 to its Form S-1 registration statement with the SEC.
  • The filing pertains to the resale of up to 11,046,927 shares of common stock by the selling stockholders.
  • This includes 6,851,574 outstanding shares and 4,195,353 shares obtainable upon the exercise of warrants.
  • The shares and warrants were acquired through private placement equity financings and third-party purchases between 2019 and 2023.
  • Key selling stockholders include Moshe (Mori) Arkin (offering 7,131,609 shares) and The Phoenix Holdings (offering 3,673,711 shares).
  • Mr. Arkin, a director, beneficially owns approximately 52.07% of the common stock and holds approximately 42.15% of the current voting power.
  • Warrants for 3,294,117 shares can be exercised at $5.50 per share, below the market price of $5.76 as of August 1, 2024.
  • The company will not receive proceeds from the stock sale but could receive up to $27.4 million if all warrants are exercised for cash.
  • The common stock is quoted on the OTCQB Market under the symbol ODYS.
  • The document outlines risks associated with investing in Odysight.ai securities.

Sentiment

Score: 4

Explanation: The document is largely factual, but the potential for stock dilution and price decline creates a slightly negative outlook.

Positives

  • Potential for the company to receive $27.4 million if all warrants are exercised for cash, which will be used for working capital and general corporate purposes.
  • The company is expanding its research and development activities workforce in the domain of I4.0, sales and marketing activities to promote its solutions and capital expenditures.

Negatives

  • The selling stockholders may exercise their warrants at below-market prices, which would be dilutive of current stockholders.
  • The resale of shares could cause a significant decline in the trading price of the common stock.
  • Mr. Arkin will likely control any action requiring a stockholder vote and, were Mr. Arkin to sell shares pursuant to this offering, such sales could result in a change of control of the Company.

Risks

  • The number of shares of common stock that the Selling Stockholders can sell into the public markets pursuant to this prospectus greatly exceeds the Companys public float.
  • The resale of the shares of common stock pursuant to this prospectus could cause a significant decline in the trading price of the common stock.
  • Future resales of Common Stock may cause the market price of our Common Stock to drop significantly, even if our business is doing well.
  • Trading on the OTC Markets is volatile, sporadic and often thin, which could depress the market price of our Common Stock and make it difficult for our stockholders to resell their Common Stock.
  • If the ownership of our Common Stock continues to be highly concentrated, it may prevent you and other minority stockholders from influencing significant corporate decisions and may result in conflicts of interest.
  • If our majority stockholder, Mr. Arkin, sells shares of Common Stock pursuant to this offering, such sales could result in a change of control of the Company.

Future Outlook

The Selling Stockholders may sell any, all or none of the shares of common stock offered by this prospectus. We do not know when or in what amounts the Selling Stockholders may offer the shares of common stock for sale.

Industry Context

The document does not provide specific industry context beyond mentioning the OTCQB market. Further analysis would require comparing Odysight.ai's situation to other companies in similar industries and stages of development.

Stakeholder Impact

  • Current stockholders may experience dilution if warrants are exercised.
  • The share price could be negatively impacted by the resale of a large number of shares.

Next Steps

  • The selling stockholders may offer the shares of Common Stock covered by this prospectus directly to purchasers, through agents selected by the Selling Stockholders, or to or through underwriters or dealers.

Key Dates

DateDescription
2019-12-30Intellisense and Medigus Ltd. entered into an Exchange Agreement.
2019-12-31Intellisense changed its name to ScoutCam Inc.
2020-02-01Start date of ODYS:TwoThousandAndTwentyShareIncentivePlanMember.
2021-01-20Date of ODYS:BoardOfDirectorsMember.
2023-03-15Start date of ODYS:StockPurchaseAgreementsMember.
2023-06-05ScoutCam Inc. changed its name to Odysight.ai Inc.
2024-08-01Date of the prospectus, with ODYS stock price at $5.76.

Keywords

common stock, warrants, resale, private placement, selling stockholders, ODYS, OTCQB, equity financing, Arkin, Phoenix Holdings, dilution

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.